The US Food and Drug Administration (FDA) is now “open to bayesian statistics,” contrasting this with the frequentist approach that the agency and the drug industry have historically relied on for ...
Jessica Ritsick, Yifan Wang, Ph.D. Our FDA: Drug & Device Team analyzes the Food and Drug Administration’s new guidance on Bayesian approaches to innovative drug trials, providing greater clarity on ...
For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results